A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective. To evaluate the effects of once-weekly dulaglutide injection and once-daily glimepiride on glucose fluctuation in patients with type 2 diabetes mellitus (T2DM) using the Continuous Glucose Monitoring System (CGMS). Methods. A total of 23 patients with T2DM were randomly assigned into two groups for 26 weeks: the dulaglutide group (n=13) and the glimepiride group (n=10). 72-hour CGMS was applied to all patients: before and after the treatment. General clinical data were collected and measured, such as fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), tumor necrosis factor-α (TNF-α), 8-iso-prostaglandin F2 α (8-iso-PGF2 α), and interleukin-6 (IL-6). Results. HbA1c of the dulaglutide group was reduced from 8.38±0.93% to 6.68±0.73% after the treatment (P<0.05); similarly, it was reduced from 7.91±0.98% to 6.67±0.74% (P<0.05) in the glimepiride group. The levels of serum 8-iso-PGF2 α, TNF-α, and IL-6 all decreased significantly in both groups after treatment, and there was no significant difference found between the two groups (P>0.05). The Mean Blood Glucose (MBG) of the two groups declined significantly after therapy (P<0.05). However, the Standard Deviation of Blood Glucose (SDBG) decreased significantly only in the dulaglutide group (from 2.57±0.74 mmol/L to 1.98±0.74 mmol/L, P<0.05). There were no significant changes of Mean Amplitude of Glycemic Excursion (MAGE) and Absolute Means of Daily Difference (MODD) after treatment in both groups. Furthermore, no statistically significant difference was found between the two groups in MBG, SDBG, MAGE, and MODD (P>0.05). The percentage time (PT) (>10 mmol/L and 3.9-10 mmol/L) of the two groups was significantly changed after the treatment (P<0.05). However, this was not seen in the PT<3.9 mmol/L after the treatment (P>0.05). Conclusion. Once-weekly dulaglutide injection has the same effectiveness as daily glimepiride on lowering blood glucose and decreasing oxidation stress and inflammation and is more effective in controlling glucose fluctuation as compared with glimepiride. This trial is registered with ClinicalTrials.gov NCT01644500.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ceriello, A., Esposito, K., Piconi, L., Ihnat, M. A., Thorpe, J. E., Testa, R., Boemi, M., & Giugliano, D. (2008) · Diabetes · doi:10.2337/db08-0063 · Cited by 1,310
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284
Guo, C., Huang, T., Chen, A., Chen, X., Wang, L., Shen, F., & Gu, X. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165826 · Cited by 112
Boustani, M. A., Pittman, I., Yu, M., Thieu, V. T., Varnado, O. J., & Juneja, R. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12687 · Cited by 46
Research works printed but not linked: 16
- 10.1016/j.diabres.2013.11.002 · DOI · Paper page
- 10.1016/S2213-8587(14)70144-5 · DOI · Paper page
- 10.2147/PPA.S151736 · DOI · Paper page
- 10.2337/dc13-2759 · DOI · Paper page
- 10.1186/s12933-015-0275-3 · DOI
- 10.2337/dc12-2220 · DOI
- 10.1186/1475-2840-12-1 · DOI · Paper page
- 10.1001/jama.295.14.1681 · DOI · Paper page
- 10.1155/2016/1028945 · DOI
- 10.4158/EP161337.OR · DOI
- 10.1111/dom.12671 · DOI
- 10.1161/HYPERTENSIONAHA.114.03062 · DOI · Paper page
- 10.1111/dom.12816 · DOI · Paper page
- 10.1186/s12933-016-0355-z · DOI · Paper page
- 10.1016/S1134-3230(10)64002-1 · DOI
- 10.1111/dom.12705 · DOI · Paper page
Cited by
Overview of oxidative stress and inflammation in diabetes
Weinberg Sibony, R., Segev, O., Dor, S., & Raz, I. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70014 · Cited by 292
Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?
Katsiki, N., & Ferrannini, E. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107723 · Cited by 91
“001) at 26 weeks.(99) No study investigated the effects of dulaglutide on ferritin.”
BackgroundRen, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59
Balogh, D. B., Wagner, L. J., & Fekete, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097789 · Cited by 38
Metadata
- Authors
- Li, H., Xu, X., Wang, J., Kong, X., Chen, M., Jing, T., Zhang, Z., Yin, G., Liu, X., Hu, Y., Ye, L., Su, X., & Ma, J.
- Venue
- Journal of Diabetes Research
- Publisher
- Wiley
- Published
- 2019-04-30
- Volume
- 2019
- Pages
- 1-7
- ISSN
- 2314-6745 (ISSN-L)
- 2314-6753
- OpenAlex
- W2943787579
- Cited by
- 21
- References
- 5
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Scientific and Technological Development Program of Jiangsu Province of China (BL2014010)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up. https://app.cochat.ai/papers/10.1155/2019/6423987
- The paper
- Li, H., Xu, X., Wang, J., Kong, X., Chen, M., Jing, T., Zhang, Z., Yin, G., Liu, X., Hu, Y., Ye, L., Su, X., & Ma, J. (2019). A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up. Journal of Diabetes Research. https://doi.org/10.1155/2019/6423987
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.